Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Sunrun Inc (RUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Sunrun Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Sunrun Inc trades at $12.48 (market cap $2.97B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13.4× Sunrun Inc's market cap, and Sunrun Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | RUN | |
|---|---|---|
Market Cap | $39.89B | $2.97B |
Sector | Health | Technology |
52-Week High | $491.22 | $21.41 |
52-Week Low | $278.09 | $9.07 |
Enterprise Value | $38.15B | $17.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Sunrun (RUN) trades at $12.47, up 0.08% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong profitability with a net income margin of 17.88% and ROE of 19.06%, while launching a distributed AI data center pilot to leverage its home energy assets. Analyst consensus is bullish with a $17.45 price target, but cash flow from operations remains negative, highlighting financial strain.
The outlook for RUN is mixed: growth potential from virtual power plant initiatives and AI partnerships offers upside, but negative operating cash flow and high debt pose significant risks. Investors should weigh the attractive valuation multiples against operational sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
